Chargement en cours...
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards and underlying risk factors for cardiovascular adverse events associated with carfilzomib. Thi...
Enregistré dans:
| Publié dans: | Cancer Med |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7826471/ https://ncbi.nlm.nih.gov/pubmed/33169938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3568 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|